Beer becomes Aegerion CEO

> Marc Beer has joined Aegerion Pharmaceuticals as CEO and a member of the board of directors. Aegerion release

> SARcode has announced that Quinton Oswald has joined the company as CEO. SARcode release

> AAIPharma Services has appointed Patrick Walsh as CEO. AAIPharma release

> MethylGene has reported that Donald Corcoran has resigned as president and CEO and as director of the company. MethylGene release

> Probiodrug AG has tapped Kumar Srinivasan as chief business officer. Probiodrug report

> CytoGenix has announced the resignation of Randy Moseley, CFO and chairman of the board, from all positions within the company. Steven Plumb will now serve as CFO of CytoGenix, while Cy Stein has been appointed as chairman of the board. CytoGenix release | Release

> Prometheus Laboratories has named Declan Doogan as executive VP and chief medical officer. Prometheus release

> InVivo Therapeutics has announced that Christopher Pritchard will assume the role of chief science officer. InVivo release

> BioClinica has appointed Garry Johnson as senior VP and chief technology officer, a newly created position. BioClinica release

>  AVEO Pharmaceuticals has appointed Michael Bailey to the newly created role of chief commercial officer, as well as the addition of Donna Radzik in the newly created role of VP, technical operations. AVEO release

> Ensemble appoints Ted Hibben as senior VP, corporate development. Ensemble release

> Dendreon has reported that Ian Clark, CEO and head of North American commercial operations at Genentech, a wholly-owned member of the Roche Group, has resigned from the company's board of directors. Dendreon release

> Creabilis SA has announced the appointment of George Horner III as its chairman. Creabilis release

> Kane Biotech has named Philip Renaud to its board of directors. Kane release

> Rexahn Pharmaceuticals has named Peter Brandt and Richard Kivel to the company's board of directors. Rexahn release

> Bruce Peacock hsa joined Discovery Labs' board of directors. Discovery release

> CT Atlantic AG has named Thomas Lander to its board of directors. CT Atlantic's release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.